A prospective study assessing preoperative and postoperative plasma Fibulin-2 levels will provide more data on its potential role as a biomarker for monitoring progression (in 19.5–46% of patients treated for a recurrence) [13,44] of grade I meningiomas or recurrence (in 39–58%) [6] of grade II meningiomas. The gene discussed is FBLN2; the disease is meningioma.